FOLLOWUS
Integration of chinese medicine with western medicine could lead to future medicine: molecular module medicine
- Chinese Journal of Integrative Medicine Vol. 22, Issue 4, Pages: 243-250(2016)
- Affiliations：
1. Institute for Advancing Translational Medicine in Bone and Joint Diseases, Hong Kong Baptist University,Hong Kong SAR,China
2. Cardiovascular Disease Centre, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
- Author bio：
- Funds：
DOI：10.1007/s11655-016-2495-0
CLC：Published：2016，
Published Online：9 April 2016，
Scan for full text
Zhang, C., Zhang, G., Chen, Kj. et al. Integration of chinese medicine with western medicine could lead to future medicine: molecular module medicine., Chin. J. Integr. Med. 22, 243–250 (2016). https://doi.org/10.1007/s11655-016-2495-0
Chi Zhang, Ge Zhang, Ke-ji Chen, et al. Integration of chinese medicine with western medicine could lead to future medicine: molecular module medicine. [J]. Chinese Journal of Integrative Medicine 22(4):243-250(2016)
Zhang, C., Zhang, G., Chen, Kj. et al. Integration of chinese medicine with western medicine could lead to future medicine: molecular module medicine., Chin. J. Integr. Med. 22, 243–250 (2016). https://doi.org/10.1007/s11655-016-2495-0 DOI：
Chi Zhang, Ge Zhang, Ke-ji Chen, et al. Integration of chinese medicine with western medicine could lead to future medicine: molecular module medicine. [J]. Chinese Journal of Integrative Medicine 22(4):243-250(2016) DOI： 10.1007/s11655-016-2495-0.
摘要
The development of an effective classification method for human health conditions is essential for precise diagnosis and delivery of tailored therapy to individuals. Contemporary classification of disease systems has properties that limit its information content and usability. Chinese medicine pattern classification has been incorporated with disease classification
and this integrated classification method became more precise because of the increased understanding of the molecular mechanisms. However
we are still facing the complexity of diseases and patterns in the classification of health conditions. With continuing advances in omics methodologies and instrumentation
we are proposing a new classification approach: molecular module classification
which is applying molecular modules to classifying human health status. The initiative would be precisely defining the health status
providing accurate diagnoses
optimizing the therapeutics and improving new drug discovery strategy. Therefore
there would be no current disease diagnosis
no disease pattern classification
and in the future
a new medicine based on this classification
molecular module medicine
could redefine health statuses and reshape the clinical practice.
Abstract
The development of an effective classification method for human health conditions is essential for precise diagnosis and delivery of tailored therapy to individuals. Contemporary classification of disease systems has properties that limit its information content and usability. Chinese medicine pattern classification has been incorporated with disease classification
and this integrated classification method became more precise because of the increased understanding of the molecular mechanisms. However
we are still facing the complexity of diseases and patterns in the classification of health conditions. With continuing advances in omics methodologies and instrumentation
we are proposing a new classification approach: molecular module classification
which is applying molecular modules to classifying human health status. The initiative would be precisely defining the health status
providing accurate diagnoses
optimizing the therapeutics and improving new drug discovery strategy. Therefore
there would be no current disease diagnosis
no disease pattern classification
and in the future
a new medicine based on this classification
molecular module medicine
could redefine health statuses and reshape the clinical practice.
关键词
classification of diseaseChinese medicine pattern classificationmolecular module medicinemethodology
Keywords
classification of diseaseChinese medicine pattern classificationmolecular module medicinemethodology
references
Lu AP, Chen KJ. Integrative medicine in clinical practice: from pattern differentiation in traditional Chinese medicine to disease treatment. Chin J Integr Med 2009;15:152.
Robinson PN. Classification and coding of rare diseases: overview of where we stand, rationale, why it matters and what it can change. Orphanet J Rare Dis 2012;7(Suppl 2):A10.
Menche J, Sharma A, Kitsak M, Ghiassian SD, Vidal M, Loscalzo J. Uncovering disease-disease relationships through the incomplete interactome. Science 2015;347:1257601.
Lee E, Chuang HY, Kim JW, Ideker T, Lee D. Inferring pathway activity toward precise disease classification. PLoS Comput Biol 2008;4:e1000217.
Ferreira AS, Lopes AJ. Chinese medicine pattern differentiation and its implications for clinical practice. Chin J Integr Med 2011;17:818–823.
Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011;12:56–68.
Wagner GP, Pavlicev M, Cheverud JM. The road to modularity. Nat Rev Genet 2007;8:921–931.
Wu JM, Montgomery E. Classification and pathology. Surgic Clin North Am 2008;88:483–520.
Csermely P, Agoston V, Pongor S. The effi ciency of multitarget drugs: the network approach might help drug design. Trends Pharmacol Sci 2005;26:178–182.
Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4:682–690.
Leape LL. Error in medicine. JAMA 1994;272:1851–1857.
Gawande A, ed. Complications: a surgeon's notes on an imperfect science. London: Profi le Books;2010:288.
Megnien JL, Simon A, Gariepy J, Denarie N, Cocaul M, Linhart A, et al. Preclinical changes of extracoronary arterial structures as indicators of coronary atherosclerosis in men. J Hypertens 1998;16:157–163.
Fried LP, Young Y, Rubin G, Bandeen-Roche K; WHAS II Collaborative Research Group. Self-reported preclinical disability identifies older women with early declines in performance and early disease. J Clin Epidemiol 2001;54:889–901.
Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, et al. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography fi ndings. Arch Neurol 2009;66:632–637.
Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012;8:1–13.
Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386:743–800.
Indrayan A, ed. Medical biostatistics. Boca Raton: CRC Press; 2012:1008.
Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273:1516–1517.
Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a crosssectional study. Lancet 2012;380:37–43.
Benjamin RM. Multiple chronic conditions: a public health challenge. Public Health Rep 2010;125:626–627.
Fortin M, Bravo G, Hudon C, Vanasse A, Lapointe L. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med 2005;3:223–228.
Valderas JM, Starfi eld B, Sibbald B, Salisbury C, Roland M. Defi ning comorbidity: implications for understanding health and health services. Ann Fam Med 2009;7:357–363.
Starfield B. Threads and yarns: weaving the tapestry of comorbidity. Ann Fam Med 2006;4:101–103.
Fortin M, Soubhi H, Hudon C, Bayliss EA, van den Akker M. Multimorbidity's many challenges. BMJ 2007;334:1016–1017.
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defi ning comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130–1139.
Piccirillo JF, Feinstein AR. Clinical symptoms and comorbidity: signifi cance for the prognostic classification of cancer. Cancer 1996;77:834–842.
Ritchie C. Health care quality and multimorbidity: the jury is still out. Med Care 2007;45:477–479.
Bentsen BG. International classification of primary care. Scand J Prim Health Care 1986;4:43–50.
van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what's in a name? A review of literature. Eur J Gener Pract 1996;2:65–70.
Huang W, Wang P, Liu Z, Zhang L. Identifying disease associations via genome-wide association studies. BMC Bioinformatics 2009;10(Suppl 1):S68.
del Sol A, Balling R, Hood L, Galas D. Diseases as network perturbations. Curr Opin Biotechnol 2010;21: 566–571.
Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, Brown PA, et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater 2011;10:389–397.
Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290–300.
Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIVinfected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081–1090.
Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorders: implications for state mental health policy. Schizophr Bull 2002;28:75–84.
Piot P, Bartos M, Ghys PD, Walker N, Schwartlander B. The global impact of HIV/AIDS. Nature 2001;410:968–973.
Petricoin EF, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, et al. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol 2005;23:3614–3621.
Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. Nature Clin Pract Oncol 2006;3:448–457.
van der Greef J, McBurney RN. Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov 2005;4:961–967.
Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5:993–996.
Butcher EC, Berg EL, Kunkel EJ. Systems biology in drug discovery. Nat Biotechnol 2004; 22:1253–1259.
Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin Oncol 1999;26(4 Suppl 12):71–77.
Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26(4 Suppl 12):60–70.
Csermely P, Korcsmáros T, Kiss HJ, London G, Nussinov R. Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther 2013;138:333–408.
Ko TWK, Stephenson SL, Bahkali AH, Hyde KD. From morphology to molecular biology: can we use sequence data to identify fungal endophytes? Fung Divers 2011;50:113–120.
Birch S, Alraek T. Traditional East Asian medicine: how to understand and approach diagnostic fi ndings and patterns in a modern scientific framework? Chin J Integr Med 2014;20:336–340.
Niu X, Lu C, Xiao C, Ge N, Jiang M, Li L, et al. The crosstalk of pathways involved in immune response maybe the shared molecular basis of rheumatoid arthritis and type 2 diabetes. PLos One 2015;10:e0134990.
Niu X, Lu C, Xiao C, Zhang Z, Jiang M, He D, et al. The shared crosstalk of multiple pathways involved in the inflammation between rheumatoid arthritis and coronary artery disease based on a digital gene expression profi le. PLos One 2014;9:e113659.
Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, Goehler H, et al. A human protein-protein interaction network: a resource for annotating the proteome. Cell 2005;122:957–968.
Zanzoni A, Soler-López M, Aloy P. A network medicine approach to human disease. FEBS Lett 2009;583:1759–1765.
Jia J, Zhu F, Ma X, Cao Z, Li Y, Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 2009;8:111–128.
Yildirim MA, Goh KI, Cusick ME, Barabási AL, Vidal M. Drug-target network. Nat Biotechnol 2007;25:1119–1126.
Wagner GP, Pavlicev M, Cheverud JM. The road to modularity. Nat Rev Genet 2007;8:921–931.
Barabasi AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004;5:101–113.
Miller JA, Oldham MC, Geschwind DH. A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging. J Neurosci 2008;28:1410–1420.
Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356–361.
Wermuth CG. Multitargeted drugs: the end of the 'onetarget-one-disease'philosophy? Drug Discov Today 2004;9:826–827.
Oprea TI, Bauman JE, Bologa CG, Buranda T, Chigaev A, Edwards BS, et al. Drug repurposing from an academic perspective. Drug Discov Today Ther Strateg 2012;8:61–69.
Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and nonvascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379:1602–1612.
Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007;448:645–646.
Harris L, Downar E, Shaikh NA, Chen T. Antiarrhythmic potential of chloroquine: new use for an old drug. Can J Cardiol 1988;4:295–300.
Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet 2012;380:601–610.
Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008;32:962–969.
Pujol A, Mosca R, Farrés J, Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci 2010;31:115–123.
Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295–1300.
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694–1703.
Rask-Andersen M, Almén MS, Schiöth HB. Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 2011;10:579–590.
Zhao S, Li S. A co-module approach for elucidating drug–disease associations and revealing their molecular basis. Bioinformatics 2012;28:955–961.
Bunnage ME. Getting pharmaceutical R&D back on target. Nat Chem Biol 2011;7:335–339.
Russell C, Rahman A, Mohammed AR. Application of genomics, proteomics and metabolomics in drug discovery, development and clinic. Ther Deliv 2013;4:395–413.
0
Views
0
Downloads
3
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
